A new group of MPs and peers, with the support of the BioIndustry Association (BIA), has written to the Chancellor, urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget.
Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies.
The UK is a global leader in TechBio, drawing substantial investments and nurturing a vibrant ecosystem of talent and businesses, reveals a report launched today by the BIA.
Read the BIA's 2024 TechBio report to learn the current state of the sector and to read case studies from companies on the vanguard of innovation within the field.
Pioneer Group welcomed 425 school children from 29 schools to eight of its sites across the UK this week to mark Ada Lovelace Day, an international celebration of the achievements of women in STEM.
Today marks a pivotal moment for our Association as a key strategic objective has been realised: the new government has placed growth at the centre of its agenda, with life sciences positioned as a cornerstone of that plan.
In this blog, Izzy Webb outlines why the UK has published voluntary guidance to promote synthetic nucleic acid screening and who the guidance is intended for.
In this insightful blog, Louis Taylor, CEO of the British Business Bank, explores how the Mansion House reforms and increased pension fund investments could unlock billions in domestic capital, fueling the next generation of UK innovators.
Symbiosis Pharmaceutical Services Ltd announces the purchase of new premises in Stirling, Scotland, UK. The additional space will double the total footprint of the company across the four facilities that it will operate from, increasing manufacturing capacity by 50% in the short-term.
2024 continues to be a big year for US politics. As well as a presidential election, there are several pieces of legislation that either are affecting or will affect our sector. Watch the recording to learn more about all three of these developments, and what it will mean for you as a UK biotech.
Microbiotica announces that the first patient has been dosed in its advanced melanoma (MELODY-1) trial. This international trial is due to recruit up to 40 patients at clinical centres in the UK, France, Italy and Spain. Initial data readouts are expected by the end of 2025.
The government's plan to put life sciences up in lights this Sunday ahead of the International investment Summit was somewhat overtaken by the news of the reorganisation of Keir Starmer's Number 10 team which dominated headlines. Nevertheless, it's been a busy week of announcements affecting our sector.
Pioneer Group has announced its successful exit from Alderley Analytical, a leading independent contract research organisation (CRO) specialising in bioanalytical services, following the company’s acquisition by Synexa Life Sciences Ltd, a Dutch-based company backed by major European healthcare investor Gilde Healthcare.
The BIA’s policy and public affairs team attended the conferences of the three major UK parties this year. This is a key point in the political calendar and allows us to highlight the sector through fringe events, meet policymakers, and get a sense of the political environment.
Ingenza, a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator, has signed a 10-year lease at the Moubray Building at Edinburgh Technopole, part of Pioneer Group.
Dr Peter Bloomfield is the Director of Research at the Macular Society. In this guest blog, he lays out the problem posed by macular disease and his hope for a solution. He also gives insight into why the Macular Society joined the BIA.
